Inflammatory myopathy: Difference between revisions

Jump to navigation Jump to search
Line 182: Line 182:
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
Line 253: Line 253:
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Anti−SRP and anti−HMGCoAR [[Autoantibody|autoantibodies]]
* Anti−SRP and anti−HMGCoAR [[Autoantibody|autoantibodies]]
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
*'''↑↑↑'''
*↑↑↑
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Minimal or no inflammatory infiltrates and marked muscle [[necrosis]]
* Minimal or no inflammatory infiltrates and marked muscle [[necrosis]]

Revision as of 21:08, 2 May 2018

Inflammatory Myopathy

Home

Overview

Classification

Differentiating Inflammatory myopathy from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]

Overview

Classification

The 2017 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathy Score
Variable No muscle biopsy With muscle biopsy
Age of onset ≥ 18 and < 40 years 1.3 1.5
Age of onset ≥ 40 years 2.1 2.2
Objective symmetric weakness, usually progressive, of the proximal upper extremities 0.7 0.7
Objective symmetric weakness, usually progressive, of the proximal lower extremities 0.8 0.5
Neck flexors are relatively weaker than neck extensors 1.9 1.6
In the legs, proximal muscles are relatively weaker than distal muscles 0.9 1.2
Heliotrope rash 3.1 3.2
Gottron’s papules 2.1 2.7
Gottron’s sign 3.3 3.7
Dysphagia or esophageal dysmotility 0.7 0.6
Anti−Jo1 autoantibody present 3.9 3.8
Elevated serum levels of CK or LDH* or ASAT/AST/SGOT* or ALAT/ALT/SGPT* 1.3 1.4
Endomysial infiltration of mononuclear cells surrounding, but not invading, myofibers on muscle biopsy 1.7
Perifascicular atrophy 1.9
Rimmed vacuoles 3.1

Probability of IIM including muscle biopsy=1/[1+exponential (5.33–score)]

Probability of IIM without muscle biopsy=1/[1+exponential (6.49–score)]

To use the calculator to assess the probability of IIM, click here.

Classification algorithm for subgroups of IIM

Abbreviation: ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; IIM, idiopathic inflammatory myopathies;

 
 
 
 
 
 
 
 
 
 
 
 
A patient meets the EULAR/ACR classification criteria for IIM (probability of IIM ≥55%)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age of onset 0-17 years old
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
 
 
 
 
 
 
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Skin manifestations include Heliotrope rash, Gottron's papules, or Gottron's sign
 
 
 
 
 
 
 
 
Skin manifestations include Heliotrope rash, Gottron's papules, or Gottron's sign
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
 
 
 
 
Yes
 
 
No
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical features include finger flexor weakness, or no treatment response,
or Muscle biopsy includes rimmed vacuoles
 
 
 
 
 
Muscle weakness manifested as objective progressive symmetric muscle weakness of proximal upper or lower extremities, neck flexors relatively weaker than extensors, or in the legs proximal muscles relatively weaker than distal
 
 
Juvenile myositis other than juvenile dermatomyositis
 
Juvenile dermatomyositis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
Yes
 
No
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Polymyositis,
or immune-mediated necrotizing myopathy
 
Inclusion body myositis
 
Amyopathic dermatomyositis
 
Dermatomyositis
 

Differentiating Inflammatory Myopathy from other Diseases

Organ system Disease Age of onset Muscle weakness Fever Myalgia Contractures Gait abnormality Neuropathy Atrophy Stiffness Myoglobinuria Other features History Physical

Examination

Laboratory Findings Creatine Kinase Muscle Biopsy Electromyogram
Inflammatory/ Rheumatologic Dermatomyositis[6] 40s−50s

Can affect children

Proximal + + +
  • ↑↑
  • Perimysial mononuclear infiltrate
Polymyositis[7] > 18 years Proximal + + +
  • N/A
  • N/A
  • ↑↑
  • Endomysial mononuclear infiltrate
  • Patchy necrosis
Inclusion body myositis[8] 50s Proximal

& distal

  • N/A
  • Antibodies to cytoplasmic 5'−nucleotidase
  • ↑↑
Immune−mediated necrotizing myopathies (IMNM)[9][10] 30s−70s Proximal
  • N/A
  • ↑↑↑
  • Minimal or no inflammatory infiltrates and marked muscle necrosis
Amyopathic dermatomyositis[11] 40s−60s
  • Rash
  • Pruritus
  • Photosensitivity
  • N/A
  • Heliotrope rash on face and hands
  • Gottron's sign ( violaceous scaly eruption )
  • Normal
  • Normal
  • Normal
  • Normal
Fibromyalgia[12] 40−50s Generalized +
  • Normal
  • Normal
  • Normal
  • Normal
Polymyalgia Rheumatica[13] 50s Diffuse + + +
  • History of joints stiffness, worse in the morning
  • Restricted shoulder motion
  • Normal
  • Normal
  • Normal
Organ system Disease Age of onset Muscle weakness Fever Myalgia Contractures Gait abnormality Neuropathy Atrophy Stiffness Myoglobinuria Other features History Physical

Examination

Laboratory Findings Creatine Kinase Muscle Biopsy Electromyogram

References

  1. Leclair V, Lundberg IE (March 2018). "New Myositis Classification Criteria-What We Have Learned Since Bohan and Peter". Curr Rheumatol Rep. 20 (4): 18. doi:10.1007/s11926-018-0726-4. PMC 5857275. PMID 29550929.
  2. Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Dankó K, Dimachkie MM, Feldman BM, Torre IG, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG (December 2017). "2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups". Ann. Rheum. Dis. 76 (12): 1955–1964. doi:10.1136/annrheumdis-2017-211468. PMID 29079590.
  3. Hilton-Jones, David (2011). "Observations on the classification of the inflammatory myopathies". La Presse Médicale. 40 (4): e199–e208. doi:10.1016/j.lpm.2010.10.035. ISSN 0755-4982.
  4. Benveniste, Olivier; Léger, Jean-Marc (2011). "Inflammatory or necrotizing myopathies, myositides and other acquired myopathies, new insight in 2011". La Presse Médicale. 40 (4): e197–e198. doi:10.1016/j.lpm.2011.02.002. ISSN 0755-4982.
  5. Lundberg, Ingrid E.; Tjärnlund, Anna; Bottai, Matteo; Werth, Victoria P.; Pilkington, Clarissa; de Visser, Marianne; Alfredsson, Lars; Amato, Anthony A.; Barohn, Richard J.; Liang, Matthew H.; Singh, Jasvinder A.; Aggarwal, Rohit; Arnardottir, Snjolaug; Chinoy, Hector; Cooper, Robert G.; Dankó, Katalin; Dimachkie, Mazen M.; Feldman, Brian M.; Garcia-De La Torre, Ignacio; Gordon, Patrick; Hayashi, Taichi; Katz, James D.; Kohsaka, Hitoshi; Lachenbruch, Peter A.; Lang, Bianca A.; Li, Yuhui; Oddis, Chester V.; Olesinska, Marzena; Reed, Ann M.; Rutkowska-Sak, Lidia; Sanner, Helga; Selva-O'Callaghan, Albert; Song, Yeong-Wook; Vencovsky, Jiri; Ytterberg, Steven R.; Miller, Frederick W.; Rider, Lisa G. (2017). "2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups". Arthritis & Rheumatology. 69 (12): 2271–2282. doi:10.1002/art.40320. ISSN 2326-5191.
  6. Dalakas MC (1991). "Polymyositis, dermatomyositis and inclusion-body myositis". N Engl J Med. 325 (21): 1487–98. doi:10.1056/NEJM199111213252107. PMID 1658649.
  7. Dalakas MC (1991). "Polymyositis, dermatomyositis and inclusion-body myositis". N Engl J Med. 325 (21): 1487–98. doi:10.1056/NEJM199111213252107. PMID 1658649.
  8. Dalakas MC (1991). "Polymyositis, dermatomyositis and inclusion-body myositis". N Engl J Med. 325 (21): 1487–98. doi:10.1056/NEJM199111213252107. PMID 1658649.
  9. Basharat, Pari; Christopher-Stine, Lisa (2015). "Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management". Current Rheumatology Reports. 17 (12). doi:10.1007/s11926-015-0548-6. ISSN 1523-3774.
  10. Bergua, C.; Chiavelli, H.; Simon, J. P.; Boyer, O.; Jouen, F.; Stenzel, W.; Martinet, J. (2016). "Immune-mediated necrotizing myopathy". Zeitschrift für Rheumatologie. 75 (2): 151–156. doi:10.1007/s00393-015-0029-3. ISSN 0340-1855.
  11. Olsen NJ, Park JH, King LE (August 2001). "Amyopathic dermatomyositis". Curr Rheumatol Rep. 3 (4): 346–51. PMID 11470054.
  12. Ohara N, Katada S, Yamada T, Mezaki N, Suzuki H, Suzuki A, Hanyu O, Yoneoka Y, Kawachi I, Shimohata T, Kakita A, Nishizawa M, Sone H (2016). "Fibromyalgia in a Patient with Cushing's Disease Accompanied by Central Hypothyroidism". Intern. Med. 55 (21): 3185–3190. doi:10.2169/internalmedicine.55.5926. PMC 5140872. PMID 27803417.
  13. Myklebust G, Gran JT (1996). "A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis". Br J Rheumatol. 35 (11): 1161–8. PMID 8948307.